Clinical Trial Update: Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Botox (onabotulinumtoxinA) to oxybutynin as first-line treatment for poorly compliant pediatric neurogenic bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Bladder

Drugs mentioned

• Botox (OnabotulinumtoxinA)
• oxybutynin (oxybutynin)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Neurogenic Bladder | Phase 3 | Status: COMPLETED